Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement

Show full item record



Permalink

http://hdl.handle.net/10138/328168

Citation

Biancari , F , Dahlbacka , S , Juvonen , T , Virtanen , M P O , Maaranen , P , Jaakkola , J , Laakso , T , Niemelä , M , Tauriainen , T , Vento , A , Husso , A , Savontaus , M , Laine , M , Mäkikallio , T , Raivio , P , Eskola , M , Rosato , S , Anttila , V , Airaksinen , J & Valtola , A 2020 , ' Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement ' , International Journal of Cardiology , vol. 315 , pp. 86-89 . https://doi.org/10.1016/j.ijcard.2020.03.038

Title: Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement
Author: Biancari, Fausto; Dahlbacka, Sebastian; Juvonen, Tatu; Virtanen, Marko P.O.; Maaranen, Pasi; Jaakkola, Jussi; Laakso, Teemu; Niemelä, Matti; Tauriainen, Tuomas; Vento, Antti; Husso, Annastiina; Savontaus, Mikko; Laine, Mika; Mäkikallio, Timo; Raivio, Peter; Eskola, Markku; Rosato, Stefano; Anttila, Vesa; Airaksinen, Juhani; Valtola, Antti
Contributor organization: Kardiologian yksikkö
HUS Heart and Lung Center
Helsinki University Hospital Area
Department of Surgery
Clinicum
III kirurgian klinikka
Date: 2020-09-15
Language: eng
Number of pages: 4
Belongs to series: International Journal of Cardiology
ISSN: 0167-5273
DOI: https://doi.org/10.1016/j.ijcard.2020.03.038
URI: http://hdl.handle.net/10138/328168
Abstract: Aim The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer. Methods This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017. Results In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892–1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p 
Subject: 3122 Cancers
Transcatheter aortic valve replacement
TAVR
TAVI
Cancer
Malignancy
IMPLANTATION
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: acceptedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0167527319355469_main.pdf 797.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record